Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
-
SoSe 2022
-
WiSe 2021
-
SoSe 2021
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunityIn: Cancer Cell , Jg. 43 2025, Nr. 2, S. 269 – 291.e19DOI (Open Access)
-
Baseline Pathological Liver Function Tests in Patients with Psoriasis Support the Indication for Systemic Therapy Rather than Being a Reason against it : A Real-World AnalysisIn: Psoriasis: Targets and Therapy , Jg. 15 2025, S. 29 – 44DOI (Open Access)
-
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusIn: Frontiers in Immunology , Jg. 16 2025, 1536642DOI (Open Access)
-
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanomaIn: British Journal of Dermatology: BJD , Jg. 192 2025, Nr. 3, S. 481 – 491
-
Analysis of the German Compassionate Use Program on spesolimab in patients with generalized pustular psoriasis : Evidence outside of clinical trialsIn: European Journal of Dermatology (EJD) , Jg. 34 2024, Nr. 6, S. 643 – 650
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC) , Jg. 202 2024, 113976DOI (Open Access)
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) , Jg. 200 2024, 113536DOI (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology , Jg. 15 2024, 1383125DOI (Open Access)
-
Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of colorIn: Scientific Reports , Jg. 14 2024, Nr. 1, 8740DOI, Online Volltext (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 210 2024, 114295DOI (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC) , Jg. 208 2024, 114208DOI (Open Access)
-
The Differential Diagnosis of Leg UlcersIn: Deutsches Ärzteblatt international , Jg. 121 2024, Nr. 22, S. 733 – 739DOI (Open Access)
-
The Interplay between Metabolic Adaptations and Diet in Cancer ImmunotherapyIn: Clinical Cancer Research , Jg. 30 2024, Nr. 15, S. 3117 – 3127
-
Tinea capitis due to Trichophyton soudanense and Microsporum audouinii : A surprising findingIn: JEADV Clinical Practice , Jg. 3 2024, Nr. 3, Skin Diversity, S. 887 – 890DOI, Online Volltext (Open Access)
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1395DOI (Open Access)
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer , Jg. 11 2023, Nr. 4DOI (Open Access)
-
COVID-19 vaccination in psoriasis patients receiving systemic treatment : A prospective single-center studyIn: Frontiers in Immunology , Jg. 14 2023, S. 1107438DOI (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) , Jg. 183 2023, S. 1 – 10
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: eBioMedicine , Jg. 96 2023, 104774DOI (Open Access)
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1292 – 1308DOI (Open Access)
-
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathyIn: Journal of the European Academy of Dermatology and Venereology , Jg. 37 2023, Nr. 5: Special issue on melanoma: Immune check point and BRAF‐MEK inhibitors in melanoma, S. 907 – 913DOI (Open Access)
-
Prognostic factors in the primary care of patients with Merkel cell carcinoma : A monocentric cohort study of 108 patients from a tertiary referral centreIn: JEADV Clinical Practice , Jg. 2 2023, Nr. 4, S. 810 – 818DOI, Online Volltext (Open Access)
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology , Jg. 12 2022, 879876DOI, Online Volltext (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers , Jg. 14 2022, Nr. 9, 2090DOI, Online Volltext (Open Access)
-
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma : A Multicenter, Retrospective Analysis from the German ADOReg RegistryIn: Cancers , Jg. 14 2022, Nr. 22, 5543DOI (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology , Jg. 11 2021, 725549DOI, Online Volltext (Open Access)
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC) , Jg. 150 2021, S. 119 – 129
-
Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up : A monocentre studyIn: European Journal of Cancer (EJC) , Jg. 154 2021, S. 167 – 174
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology , Jg. 11 2021, 741993DOI, Online Volltext (Open Access)
-
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma : A Retrospective Multicenter DeCOG StudyIn: Frontiers in Oncology , Jg. 11 2021, 672172DOI (Open Access)
-
Letter: Venous ulcerations occur more frequently in women on the left lower leg : Can pelvic congestion syndrome be an often undetected cause?In: International Wound Journal (IWJ) , Jg. 17 2020, Nr. 1, S. 230 – 231DOI, Online Volltext (Open Access)
-
Primary Cutaneous Diphtheria as a Rare Cause of Infectious UlcerationIn: Deutsches Ärzteblatt international , Jg. 117 2020, Nr. 51-52, S. 888DOI (Open Access)
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC) , Jg. 111 2019, S. 148 – 154DOI (Open Access)
-
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanomaIn: JCO Precision Oncology , Jg. 3 2019DOI (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC) , Jg. 113 2019, S. 47 – 54DOI (Open Access)
-
Sister Mary Joseph noduleIn: Deutsches Ärzteblatt international , Jg. 116 2019, Nr. 47, S. 798DOI (Open Access)
-
Dermatomyositis and lung cancerIn: QJM: An International Journal of Medicine , Jg. 111 2018, Nr. 3, S. 195DOI (Open Access)
-
Melkersson-Rosenthal syndromeIn: QJM: An International Journal of Medicine , Jg. 111 2018, Nr. 3, S. 199DOI (Open Access)
-
Analysis of gender-specific Differences in Response to First-line Treatment with Immunotherapy or targeted Therapy in Melanoma Patients with metastatic Stage IV Melanoma : An ADO/DeCOG Study of 2032 Patients from the prospective, multicenter Skin Cancer Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 16 – 17
-
PD-L1 Expression in Lymph Node Metastases as a Predictor of adjuvant Immunotherapy Success in Stage III Melanoma Patients: An Analysis of the prospective ADOREG Study TRIM-ADJUVANTIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 15 – 16
-
The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 17 – 18
-
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 – 28DOI (Open Access) -
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21DOI (Open Access) -
Predictors of long-term survival of Stage IV melanoma patients: a multicenter DeCOG study on 395 patients from the prospective skin cancer registry ADOREG
52. Tagung der Deutschen Dermatologischen Gesellschaft, Vereinigung Deutschsprachiger Dermatologen e. V., 26.-29.04.2023, Berlin,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S1, Special Issue: Abstractband anlässlich der 52. Tagung der Deutschen Dermatologischen Gesellschaft, Vereinigung Deutschsprachiger Dermatologen e. V. 26. bis 29. April 2023, Berlin, S. 9 – 27DOI (Open Access) -
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 – 9DOI (Open Access) -
Compartment-based proteomics of CD8high vs. CD8low melanoma regions reveals differential regulation of TOR signaling
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 12 -
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 13 – 14 -
Inhibition of the mTOR inhibitory protein sirtuin 1 leads to faster tumor growth under PD1-based immune checkpoint blockadeIn: Experimental Dermatology , Jg. 31 2022, Nr. 2, S. e92
-
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 16 – 17 -
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 19
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 6 – 7
-
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma : A prospective multicenter DeCOG studyIn: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 15_Suppl, S. 9568 – 9568DOI (Open Access)
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 58 – 59
-
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 26 – 27DOI (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. Suppl. 6, S. 3
-
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 3DOI (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 11 – 12DOI (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 38DOI (Open Access) -
Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S695 -
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 105